Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRD | O14764 | 2/20 | 0.75 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.75 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.75 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.75 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.75 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.75 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.75 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.75 |
| ▸ | KDM1A | O60341 | 2/20 | 0.67 |
| ▸ | L3MBTL3 | Q96JM7 | 3/20 | 0.65 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.65 |
| ▸ | NAMPT | P43490 | 6/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17888477 | 0.92 | GABRD (0.64) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL16565827 | 0.92 | GABRD (0.84) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL16565828 | 0.92 | GABRD (0.84) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL17888390 | 0.90 | GABRD (0.68) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL17888389 | 0.90 | GABRD (0.68) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL17888322 | 0.87 | NAMPT (0.62) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL14742135 | 0.86 | NAMPT (0.66) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL17888421 | 0.86 | GABRD (1.00) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL17886807 | 0.86 | L3MBTL3 (0.61) | GABRDGABRA1GABRB1GABRA5GABRA3 | |
| SCHEMBL19226555 | 0.86 | L3MBTL3 (0.61) | GABRDGABRA1GABRB1GABRA5GABRA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3041841-B1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | HOFFMANN LA ROCHE (CH) | 2019-06-05 | — | — | EP | disclosed |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
| WO-2010012747-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | GABRD 1304/4885GABRA1 1791/4885GABRB1 1612/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | GABRD 1304/4885GABRA1 1791/4885GABRB1 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.